18:57 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said on Oct. 19 that FDA and EMA have both pushed back their reviews of anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line non-small cell lung cancer. The...
23:32 , Oct 19, 2018 |  BC Extra  |  Company News

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Friday that FDA and EMA have both pushed back their reviews of anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line non-small cell lung cancer. The company also...
19:47 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves Pfizer's dacomitinib for first-line NSCLC

FDA approved Vizimpro dacomitinib from Pfizer Inc. (NYSE:PFE) as first-line treatment of EGFR-mutated metastatic non-small cell lung cancer. Pfizer spokesperson Jessica Smith told BioCentury the pharma will launch the drug in mid-October at a monthly...
23:37 , Sep 27, 2018 |  BC Extra  |  Company News

FDA approves Pfizer's dacomitinib for first-line NSCLC

FDA approved Vizimpro dacomitinib from Pfizer Inc. (NYSE:PFE) as first-line treatment of EGFR-mutated metastatic non-small cell lung cancer. Pfizer spokesperson Jessica Smith told BioCentury the pharma will launch the drug in mid-October at a monthly...
19:10 , May 18, 2018 |  BC Week In Review  |  Clinical News

First-line NSCLC data reported ahead of ASCO

Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co. (NYSE:BMY) each reported Phase III data for their first-line non-small cell lung cancer (NSCLC) programs in abstracts released ahead of the American Society...
23:27 , May 16, 2018 |  BC Extra  |  Clinical News

First-line NSCLC data reported ahead of ASCO

Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co. (NYSE:BMY) each reported Phase III data for their first-line non-small cell lung cancer programs in abstracts released ahead of the American Society of...
14:50 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Pfizer receives Priority Review for Dacomitinib in NSCLC

Pfizer Inc. (NYSE:PFE) said FDA accepted and granted Priority Review to an NDA for dacomitinib (PF-00299804) to treat advanced or metastatic EGFR mutation-positive non-small cell lung cancer in treatment-naïve patients. The PDUFA date is in...
17:42 , Apr 4, 2018 |  BC Extra  |  Company News

Pfizer receives Priority Review for dacomitinib in NSCLC

Pfizer Inc. (NYSE:PFE) said FDA accepted and granted Priority Review to an NDA for dacomitinib (PF-00299804) to treat advanced or metastatic EGFR mutation-positive non-small cell lung cancer in treatment-naïve patients. The PDUFA date is in...
03:12 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Pfizer reports Phase III PFS data for dacomitinib in first-line NSCLC

Pfizer Inc. (NYSE:PFE) reported data from the Phase III ARCHER 1050 trial in 452 patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (NSCLC) without CNS metastasis showing that first-line treatment with...
21:35 , Dec 16, 2016 |  BC Week In Review  |  Financial News

RiverVest financial update

RiverVest closed its Archer Seed Fund L.P. at $15 million. The firm plans to invest “modest amounts" in pre-seed and seed funding in “about 10” early stage biopharma companies. RiverVest Venture Partners , St. Louis,...